For the quarter ending 2026-03-31, JUNS made $18,652 in revenue. -$2,061,958 in net income. Net profit margin of -11054.89%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenues, net | 18,652 | 5,449* | - | - |
| Cost of goods sold | 4,362 | 1,057.75* | - | - |
| Gross profit | 14,290 | 4,391.25* | - | - |
| Research and development | 411,049 | -277,643.5* | 816,697 | 759,448 |
| General and administrative | 1,566,241 | 2,347,856.25* | 1,480,356 | 1,505,432 |
| Total operating expenses | 1,977,290 | 2,070,212.75* | 2,297,053 | 2,264,880 |
| Operating loss | -1,963,000 | -2,065,821.5* | -2,297,053 | -2,264,880 |
| Other income | - | 47,912* | - | 0 |
| Interest income | 18,404 | - | 10,212 | 13,050 |
| Gain on change in fair value of convertible notes | 1,282 | 247,039* | - | - |
| Interest expense | 118,644 | 62,528* | 1,193 | 1,135 |
| Gain on extinguishment of debt | - | - | - | 0 |
| Loss on change in fair value of derivative liability | - | - | - | 0 |
| Total other expenses, net | -98,958 | 232,423* | 9,019 | 11,915 |
| Net loss | -2,061,958 | -1,833,398.5 | -2,288,034 | -2,252,965 |
| Basic EPS | -0.06 | -0.05 | -0.07 | -0.07 |
| Diluted EPS | -0.06 | -0.05 | -0.07 | -0.07 |
| Basic Average Shares | 35,255,588 | 36,664,892 | 34,039,906 | 33,180,966 |
| Diluted Average Shares | 35,255,588 | 36,664,892 | 34,039,906 | 33,180,966 |
JUPITER NEUROSCIENCES, INC. (JUNS)
JUPITER NEUROSCIENCES, INC. (JUNS)